Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 2, 2015, Pages 463-470

  Kurano, Makoto ^a,b   Suzuki, Akiko ^a   Inoue, Asuka ^b,c   Tokuhara, Yasunori ^d,e   Kano, Kuniyuki ^c   Matsumoto, Hirotaka ^c   Igarashi, Koji ^f   Ohkawa, Ryunosuke ^d   Nakamura, Kazuhiro ^d   Dohi, Tomotaka ^g   Miyauchi, Katsumi ^g   Daida, Hiroyuki ^g   Tsukamoto, Kazuhisa ^h   Ikeda, Hitoshi ^b,d   Aoki, Junken ^b,c   Yatomi, Yutaka ^a,b,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^e KAGAWA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^f TOSOH CORPORATION   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

autotaxin; coronary disease; lysophosphatidic acids; lysophospholipids; molecular species

Indexed keywords

AUTOTAXIN; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHATIDYLGLYCEROL; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; BIOLOGICAL MARKER; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHODIESTERASE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FATTY ACID SYNTHESIS; HUMAN; LIPID OXIDATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TANDEM MASS SPECTROMETRY; THROMBOCYTE ACTIVATION; BLOOD; FEMALE; MALE; METABOLISM; PREDICTIVE VALUE; THROMBOCYTE; UPREGULATION;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; BLOOD PLATELETS; CHROMATOGRAPHY, LIQUID; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MALE; PHOSPHORIC DIESTER HYDROLASES; PLATELET ACTIVATION; PREDICTIVE VALUE OF TESTS; TANDEM MASS SPECTROMETRY; UP-REGULATION;

EID: 84922337301     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304748     Document Type: Article

References (41)

1. Pradère JP, Gonzalez J, Klein J, Valet P, Grès S, Salant D, Bascands JL, Saulnier-Blache JS, Schanstra JP. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta. 2008;1781:582-587. doi: 10.1016/j.bbalip.2008.04.001.
2. Pattanaik D, Postlethwaite AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med. 2010;10:161-167.
3. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011;30:557-565. doi: 10.1007/s10555-011-9319-7.
4. Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem. 2004;92:1086-1094. doi: 10.1002/jcb.20108.
5. Haserück N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood. 2004;103:2585-2592. doi: 10.1182/blood-2003-04-1127.
6. Pamuklar Z, Lee JS, Cheng HY, Panchatcharam M, Steinhubl S, Morris AJ, Charnigo R, Smyth SS. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol. 2008;28:555-561. doi: 10.1161/ ATVBAHA.107.151837.
7. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner JA. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest. 1999;79:1227-1235.
8. Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, Lee H. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem Biophys Res Commun. 2007;363:1001-1008. doi: 10.1016/j.bbrc.2007.09.081.
9. Tigyi G. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins. 2001;64:47-62.
10. Siess W. Athero-and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002;1582:204-215.
11. Subramanian P, Karshovska E, Reinhard P, Megens RT, Zhou Z, Akhtar S, Schumann U, Li X, van Zandvoort M, Ludin C, Weber C, Schober A. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res. 2010;107:96-105. doi: 10.1161/CIRCRESAHA.109.212647.
12. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, Dong A, Lynch K, Chun J, Morris AJ, Smyth SS. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res. 2008;103:662-670. doi: 10.1161/ CIRCRESAHA.108.180778.
13. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, Schober A. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011;13:592-600. doi: 10.1016/j.cmet.2011.02.016.
14. Spector AA. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation. 2003;108:641-643. doi: 10.1161/01.CIR.0000082307.85449.1D.
15. Smyth SS, Cheng HY, Miriyala S, Panchatcharam M, Morris AJ. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta. 2008;1781:563-570. doi: 10.1016/j.bbalip.2008.05.008.
16. Dohi T, Miyauchi K, Ohkawa R, et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin Chim Acta. 2012;413:207-212. doi: 10.1016/j.cca.2011.09.027.
17. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781:513-518. doi: 10.1016/j. bbalip.2008.06.005.
18. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H, Ohta M, Yamazaki H, Koike T, Ozaki Y. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem. 2008;45(Pt 4):364-368. doi: 10.1258/acb.2008.007242.
19. Watanabe N, Ikeda H, Nakamura K, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41:616-623. doi: 10.1097/01. mcg.0000225642.90898.0e.
20. Masuda A, Nakamura K, Izutsu K, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol. 2008;143:60-70. doi: 10.1111/j.1365-2141.2008.07325.x.
21. Nakamura K, Kishimoto T, Ohkawa R, Okubo S, Tozuka M, Yokota H, Ikeda H, Ohshima N, Mizuno K, Yatomi Y. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem. 2007;367:20-27. doi: 10.1016/j. ab.2007.05.004.
22. Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, Aoki J. Lpaproducing enzyme pa-pla(1)alpha regulates hair follicle development by modulating egfr signalling. EMBO J. 2011;30:4248-4260. doi: 10.1038/ emboj.2011.296.
23. Fukuhara S, Simmons S, Kawamura S, et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest. 2012;122:1416-1426. doi: 10.1172/JCI60746.
24. Okudaira M, Inoue A, Shuto A, Nakanaga K, Kano K, Makide K, Saigusa D, Tomioka Y, Aoki J. Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MS. J Lipid Res. 2014;55:2178-2192. doi: 10.1194/jlr.D048439.
25. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96:6931-6936.
26. Fulkerson Z, Wu T, Sunkara M, Kooi CV, Morris AJ, Smyth SS. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem. 2011;286:34654-34663. doi: 10.1074/jbc.M111.276725.
27. Billah MM, Lapetina EG. Formation of lysophosphatidylinositol in platelets stimulated with thrombin or ionophore A23187. J Biol Chem. 1982;257:5196-5200.
28. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 2003;108:741-747. doi: 10.1161/01.CIR.0000083715.37658.C4.
29. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737-48744. doi: 10.1074/jbc.M206812200.
30. Pamuklar Z, Federico L, Liu S, et al. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem. 2009;284:7385-7394. doi: 10.1074/jbc.M807820200.
31. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem. 2002;277:21197-21206. doi: 10.1074/jbc.M201289200.
32. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta. 1989;1001:282-285.
33. Kikuchi-Yanoshita R, Yanoshita R, Kudo I, Arai H, Takamura T, Nomoto K, Inoue K. Preferential hydrolysis of phosphatidylethanolamine in rat ischemic heart homogenates during in vitro incubation. J Biochem. 1993;114:33-38.
34. Park KS, Lee HY, Lee SY, Kim MK, Kim SD, Kim JM, Yun J, Im DS, Bae YS. Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. FEBS Lett. 2007;581:4411-4416. doi: 10.1016/j.febslet.2007.08.014.
35. Kohno M, Yokokawa K, Yasunari K, Minami M, Kano H, Hanehira T, Yoshikawa J. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation. 1998;98:353-359.
36. Bolen AL, Naren AP, Yarlagadda S, Beranova-Giorgianni S, Chen L, Norman D, Baker DL, Rowland MM, Best MD, Sano T, Tsukahara T, Liliom K, Igarashi Y, Tigyi G. The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation. J Lipid Res. 2011;52:958-970. doi: 10.1194/jlr.M013326.
37. Hausmann J, Kamtekar S, Christodoulou E, et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol. 2011;18:198-204. doi: 10.1038/nsmb.1980.
38. Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T, Satouchi K, Waku K, Fukuzawa K. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem J. 2002;365(Pt 3):617-628. doi: 10.1042/BJ20020348.
39. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R, Tigyi G. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med. 2004;199:763-774. doi: 10.1084/ jem.20031619.
40. Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, Kitabatake A, Aoki J, Arai H, Sobue K. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res. 2001;89:251-258.
41. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, Arai H, Sobue K. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation. 2003;108:1746-1752. doi: 10.1161/01.CIR.0000089374.35455.F3.